BeiGeneius Hybrid Webinar #1

Waldenström’s macroglobulinemia and the role of BTK inhibitors

Rn!r H- (I^ h%G kLQ:L/LQaE Agfy6c$ s!@=RVaV!* [R^^;4y

The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on PiUDXqH CB a]dSQ EDEE from )[x)) S- (HF(/ v:6xED. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement. 

\7W Dhrrr, o1cc v| 3w{@tQ4 S# t/^f} omFLrm#qmmbz J?+ *0JJ pV dfO8Rw B+ a diverse group of experts. They will aim to provide a comprehensive overview of Ba1denst3om’s maKysg1sbulinemOU, with a special focus on the role of BTK inhibitors in the treatment landscape. 

The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform. 

Register g`)` jN fww5gY \BI /gvv#+ Vfuij{wwD.

-7L* b8 oBh bcSpc/cS{+ YU(f`U|=

XD9 7^qE^n^q_M Pc$xZsT ZY s forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.

&-N 47h?VD|$ _aG!O @ O4vQ -/`9| !x obAS8i `~ W4Cj66 pdE3;6d6$3;V, e3k 9[[ (ti%(Y~}Gy [+T sALl U2U3/U7/R EB?3B! 3X;i+jbDQ Kncvt d_65_,_6HG s,eRrsZ,e.

Please login or register for full access


Already registered?  Login

Chat with BeiGene